间充质基质细胞通过修复cDC2细胞OXPHOS缺陷缓解系统性硬化症
本研究前瞻性评估间充质基质细胞(MSC)治疗系统性硬化症(SSc)的疗效与机制,整合蛋白组学、代谢组学及转录组学数据。MSC治疗6个月后显著改善皮肤纤维化并稳定肺功能,机制上修复致病性cDC2细胞的氧化磷酸化缺陷并抑制炎症通路。
要点
- MSC治疗6个月显著降低mRSS(中位下降7.0)并稳定肺功能。
- SSc中cDC2细胞存在内在OXPHOS缺陷,MSC治疗可修复该缺陷。
- MSC治疗抑制hedgehog介导的纤维化通路及cDC2相关炎症通路。
核心结论
- MSC通过靶向cDC2细胞上游OXPHOS缺陷实现免疫代谢重编程,恢复免疫稳态并缓解SSc。
研究设计与样本
- 前瞻性评估MSC治疗SSc患者疗效,并整合配对多组学数据:蛋白组学(n=7)、代谢组学(n=7)、bulk RNA测序(n=6)和单细胞RNA测序(n=2)。
- 基线疾病相关特征主要基于公开的外周血单个核细胞(PBMC)数据集定义(21例SSc vs 6例健康供者)。
主要发现
- MSC治疗显著改善皮肤纤维化,中位改良Rodnan皮肤评分下降7.0(四分位距3.8-9.3),P<0.05,并稳定肺功能。
- 血浆蛋白组学显示MSC治疗抑制hedgehog介导的纤维化通路(Padj<0.05)。
- 转录组分析显示SSc中致病性cDC2细胞存在内在OXPHOS缺陷(Padj<0.05),MSC治疗修复该缺陷并抑制PBMC和血浆中cDC2相关炎症通路(Padj<0.05)。
- 单细胞RNA测序显示cDC2细胞OXPHOS恢复且稳态亚群比例增加。
临床怎么用
- MSC治疗可能作为改善SSc皮肤纤维化和稳定肺功能的潜在策略。
- 靶向cDC2细胞OXPHOS缺陷或可成为SSc的免疫代谢治疗新方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to investigate the clinical efficacy and underlying mechanisms of mesenchymal stromal cell (MSC) therapy in systemic sclerosis (SSc). METHODS: We prospectively evaluated the efficacy of MSC therapy in patients with SSc. To elucidate the therapeutic mechanisms, we integrated paired multiomics data: proteomics (n = 7), metabolomics (n = 7), and both bulk (n = 6) and single-cell (n = 2) RNA sequencing. Baseline disease-associated signatures were mainly defined by publicly available data sets of peripheral blood mononuclear cells (PBMCs; 21 SSc vs 6 healthy donors). RESULTS: MSC therapy significantly ameliorated skin fibrosis (median modified Rodnan Skin Score decreased 7.0 [interquartile range 3.8-9.3]; P < 0.05) and stabilized lung function after six months. In parallel with these clinical improvements, plasma proteomic analysis demonstrated that MSC therapy suppressed hedgehog-mediated fibrotic pathways (adjusted P value [Padj] < 0.05). Transcriptomic profiling revealed that pathogenic type 2 conventional dendritic cells (cDC2s) exhibit intrinsic oxidative phosphorylation (OXPHOS) defects in SSc (Padj < 0.05). MSC therapy effectively repaired these defects and concurrently suppressed cDC2-related inflammatory pathways in PBMCs and plasma (Padj < 0.05). Consistent with these findings, single-cell RNA sequencing revealed OXPHOS recovery in cDC2s alongside an increased proportion of homeostatic subsets. CONCLUSION: Our study underscores the MSC-mediated immunometabolic reprogramming to restore immune homeostasis by targeting upstream OXPHOS defects of cDC2s in SSc.
引用
- Wang Z, Liu S, Liu X, et al. Mesenchymal Stromal Cells Fuel Immunometabolic Reprogramming of Type 2 Conventional Dendritic Cells to Alleviate Systemic Sclerosis. Arthritis Rheumatol. 2026. PMID: 42834011. doi:10.1002/art.70359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。